Rubric Capital Management

Edesa Biotech is a clinical-stage private company focused on developing treatments for dermatological and anorectal diseases. The initial focus is on developing novel, safe and potent alternatives to steroids for Allergic Contact Dermatitis, Hemorrhoids, and Anal Fissures. Edesa Biotech’s lead asset, EB01 is a novel non-steroidal anti-inflammatory molecule for the treatment of allergic contact dermatitis which has already demonstrated statistically significant improvements in multiple clinical studies.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.

Heron Therapeutics is a biotechnology company dedicated to developing innovative treatments for unmet medical needs, primarily in the area of nausea and pain management. Utilizing its proprietary Biochronomer drug delivery technology, the company provides sustained therapeutic levels of short-acting pharmacological agents with a single administration over several days. Heron's product offerings include SUSTOL, an extended-release injection designed to prevent nausea and vomiting associated with certain chemotherapy regimens, and CINVANTI, an intravenous formulation for managing nausea linked to highly emetogenic chemotherapy. The company is also advancing investigational products such as HTX-011, a dual-acting combination of bupivacaine and meloxicam currently in Phase III trials for pain management, and HTX-034 for postoperative pain. Founded in 1983 and headquartered in San Diego, California, Heron Therapeutics was previously known as A.P. Pharma, Inc. before rebranding in 2014.

Karyopharm Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Newton, Massachusetts, specializing in the discovery, development, and commercialization of novel drugs targeting nuclear export mechanisms for the treatment of cancer and other diseases. Its lead drug, XPOVIO (selinexor), is an approved treatment for multiple hematologic malignancies, particularly in patients with heavily pretreated multiple myeloma. The company is advancing several clinical trials for its products, including BOSTON and STORM for multiple myeloma, SADAL for relapsed or refractory diffuse large B-cell lymphoma, and SEAL for liposarcoma. Karyopharm is also exploring treatments for endometrial cancer and glioblastoma multiforme. Additionally, the company has partnerships to investigate low-dose selinexor for hospitalized COVID-19 patients and collaborates with the National Cancer Institute for cancer therapy evaluations. Karyopharm utilizes a proprietary platform to develop small molecule drugs that modulate key cellular pathways involved in cancer and inflammation.

TherapeuticsMD is a women's healthcare company based in Boca Raton, Florida, that specializes in developing and commercializing pharmaceutical products aimed at addressing health issues specific to women. The company offers several products, including IMVEXXY, a treatment for moderate-to-severe dyspareunia, and BIJUVA, a bio-identical hormone therapy for managing vasomotor symptoms. Additionally, TherapeuticsMD manufactures ANNOVERA, a contraceptive vaginal ring. Its pipeline includes preclinical projects such as TX-005HR and TX-006HR, which are transdermal creams, and TX-009HR, an oral formulation of progesterone and estradiol. The company also produces branded and generic prescription prenatal vitamins under various brands. TherapeuticsMD is focused on advancing hormone replacement therapies and has received Investigational New Drug acceptance from the U.S. Food and Drug Administration for its development candidates.